ROTHBLATT MARTINE A sold $5.3M of UTHR
ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $553.17 ($548.62–$560.79, $5.26M total) across 12 trades on 2026-07-08 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, trade date, and price range, which can influence short-term sentiment but does not change fundamentals on its own.
Market read
Traders may monitor whether additional insider sales follow, but this single Form 4 does not provide new guidance or business developments.
What to watch
The filing does not state tax, diversification, or personal liquidity drivers; traders may over-weight the signal versus the plan’s intent.
Background
The article is an SEC EDGAR Form 4 insider transaction for United Therapeutics, filed by the chairperson and CEO.
Ticker impact
SEC Form 4 shows UTHR CEO sold 9,500 shares in open-market trades for about $5.26M under a pre-arranged 10b5-1 plan.
Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.
The filing is a primary-source Form 4 disclosure with transaction size and pricing, but it does not include new company fundamentals or guidance changes.
Market effects
No direct sector read-through; this is company-specific insider activity without disclosed operational changes.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider sale disclosure.
- insiderROTHBLATT MARTINE A
Chairperson and CEO who sold shares under a 10b5-1 plan.
